Corrigendum to "Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation" [Multiple Sclerosis and Related Disorders 38 (2020) 101498]

Affiliations

• ¹ Kuopio University Hospital, Department of Neurology, Puijonlaaksontie 2, P.O. Box 100, 70029, KYS, Finland.
• ² Tampere University Hospital, Department of Neurology, Teiskontie 35, 33520, Tampere, Finland. Electronic address: ilkka.rauma@tuni.fi.
• ³ Kuopio University Hospital, Department of Neurology, Puijonlaaksontie 2, P.O. Box 100, 70029, KYS, Finland; University of Eastern Finland, Department of Neurology, Yliopistonranta 1, 70210, Kuopio, Finland.
• ⁴ University of Oulu, Research Unit of Clinical Neuroscience, P.O. Box 8000, 90014, University of Oulu, Finland; Northern Ostrobothnia Hospital District, MRC Oulu, P.O. Box 8000, 90014 University of Oulu, Finland.
• ⁵ Kuopio University Hospital, Science Service Center, Puijonlaaksontie 2, P.O. Box 100, 70029, KYS, Finland.
• ⁶ Mikkeli Central Hospital, Department of Neurology, Porrassalmenkatu 35-37, 50100, Mikkeli, Finland.
• ⁷ Tampere University Hospital, Department of Neurology, Teiskontie 35, 33520, Tampere, Finland; University of Eastern Finland, Department of Health and Social Management, Yliopistonranta 1, 70210, Kuopio, Finland.